New hope for tough blood cancers: BT02 drug trial launches
Disease control
Not yet recruiting
This study tests a new drug called BT02 in people with blood cancers (leukemia, lymphoma, or multiple myeloma) that have returned or not improved with standard treatments. About 116 adults aged 18 to 70 will receive the drug by IV every 2-3 weeks for up to 2 years. The main goals…
Phase: PHASE1, PHASE2 • Sponsor: Biotroy Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:04 UTC